Clinical profile of ST-elevation myocardial infarction thrombolysed with tenecteplase in Coronavirus Disease 2019 Pandemic: A comparative study
| Autor: | A. Rudrappa, Kamal Kant Jena, G Manohar, C. Elamaran |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Cardiovascular Complication business.industry coronavirus disease-2019 medicine.medical_treatment acute myocardial infarction Tenecteplase medicine.disease hypercoagulability St elevation myocardial infarction RC666-701 Internal medicine Pandemic Fibrinolysis medicine risk factors Diseases of the circulatory (Cardiovascular) system fibrinolysis Observational study cardiovascular diseases Myocardial infarction business medicine.drug |
| Zdroj: | Journal of Clinical and Preventive Cardiology, Vol 10, Iss 2, Pp 58-62 (2021) |
| ISSN: | 2250-3528 |
| DOI: | 10.4103/jcpc.jcpc_64_20 |
| Popis: | Background: Coronavirus disease-2019 (COVID-19) pandemic has affected millions worldwide. The various complications of COVID-19 have been discussed in the recent studies. We would like to discuss about one such cardiovascular complication, ST elevation myocardial infarction (STEMI) in COVID-19, and its characteristics in this article. Methodology: An observational study was done from April 1, 2020, to July 15, 2020, selecting all STEMI patients admitted to a tertiary care center in Chennai and treated with tenecteplase were grouped in to COVID-19 positive and negative. Their presenting features and complications and outcome were studied. Results: A total of 300 patients were admitted with STEMI during the study period, of which 11.66% were COVID-19 positive. Atherosclerotic cardiovascular risk factors were much lower in COVID-19-positive STEMI patients when compared to non-COVID STEMI patients. Mean oxygen saturation at time of presentation in COVID-19 positive and negative patients was 85.1% and 97.5%, respectively (P < 0.001). COVID-19 group had significantly higher noncardiac complications than non-COVID patients (P < 0.001). The average duration of hospital stay in COVID-19 STEMI was 13.6 days, whereas in non-COVID group was 6.8 days (P < 0.001). Higher mortality was found in the COVID-19 positive group (14.28%) when compared to non-COVID STEMI (7.9%; P < 0.001). Conclusion: COVID-19 itself is a systemic inflammatory disease, which could increase the risk of coronary plaque rupture. Thrombosis has also been described as a mechanism underlying certain cases causing presentation of STEMI, because of endothelial dysfunction and hypercoagulable state. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|